|
| [May 18, 2012] |
 |
Dr. Reddy's Announces the Launch of Clopidogrel Tablets, USP
HYDERABAD, India --(Business Wire)--
Dr. Reddy's Laboratories (NYSE: RDY) announced today that it has
launched CLOPIDOGREL TABLETS, USP 75 mg & 300 mg, a
bioequivalent generic version of PLAVIX®, in the U.S. market
on May 18, 2012. The ANDAs for Clopidogrel Tablets USP, 75 mg
& 300 mg are approved by the United States Food & Drug
Administration (USFDA). Dr. Reddy's Laboratories was among the first
applicants to submit a substantially complete ANDA for Clopidogrel
Tablets USP, 300 mg with a Paragraph IV certification, and was awarded
180 days of marketing exclusivity for this strength.
The PLAVIX® brand had U.S. sales of approximately $6.740
billion for the most recent twelve months ending March 2012 according to
IMS Health.
Dr. Reddy's Clopidogrel Tablets USP, 75 mg are available in bottle count
sizes of 30, 90 and 500, and Clopidogrel Tablets USP, 300 mg are
available in blister packs of 30's count.
Disclaimer
This ress release includes forward-looking statements, as defined in
the U.S. Private Securities Litigation Reform Act of 1995. We have based
these forward-looking statements on our current expectations and
projections about future events. Such statements involve known and
unknown risks, uncertainties and other factors that may cause actual
results to differ materially. Such factors include, but are not limited
to, changes in local and global economic conditions, our ability to
successfully implement our strategy, the market acceptance of and demand
for our products, our growth and expansion, technological change and our
exposure to market risks. By their nature, these expectations and
projections are only estimates and could be materially different from
actual results in the future.
About Dr. Reddy's
Dr. Reddy's Laboratories Ltd. (NYSE: RDY) is an integrated global
pharmaceutical company committed to providing affordable and innovative
medicines for healthier lives. Through its three businesses - Pharmaceutical
Services and Active Ingredients, Global Generics and Proprietary
Products - Dr. Reddy's offers a portfolio of products and services
including APIs, custom pharmaceutical services, generics, biosimilars,
differentiated formulations and NCEs. Therapeutic focus is on
gastro-intestinal, cardiovascular, diabetology, oncology, pain
management, anti-infective and pediatrics. Major markets include India,
USA, Russia and CIS, Germany, UK, Venezuela, S. Africa, Romania, and New
Zealand. For more information, log on to: www.drreddys.com
Plavix® is a registered trademark of Sanofi-Aventis.
IMS National Sales Perspectives: Retail and Non-Retail MAT March 2012

[ Back To SIP Phones Homepage's Homepage ]
|